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To the Editor: A striking finding 
in the study by de Steenwinkel et al. 
(1) is the high frequency of mutation 
to rifampin resistance by 2 Mycobac-
terium tuberculosis Beijing strains, 
which might play a role in the associ-
ation between the Beijing strains and 
multidrug-resistant tuberculosis. Ear-
lier reported frequency of mutation to 
rifampin resistance by M. tuberculo-
sis has been 10−8 CFU (2,3), includ-
ing the Beijing genotype (3,4). Of 
note, the Beijing 2002–1585 strain, 
for which frequency of mutation to 
rifampin resistance is 10-3 CFU (1 
mutant/1,000 CFU), showed a mod-
erate frequency of 10−8 CFU in anoth-
er study (4). We think that a mutation 
frequency increase of 100,000× is re-
markably high. In contrast, rifampin-
resistant mutants of the Beijing 1585 
strain did not emerge in low-density 
cultures (5 × 105 CFU/mL) used for 
time-kill kinetics experiments, al-
though frequency of mutation to ri-
fampin resistance was determined to 
be 10-3 CFU.
Mutation frequency is deter-
mined by fluctuation assays. To ex-
clude preexisting mutants, which 
would bias the mutation frequency by 
so-called jackpots, a series of low-in-
oculum cultures is typically used (5). 
However, for unknown reasons, de 
Steenwinkel et al. used only 1 high-
density culture of 1010 CFU of each 
strain to determine mutation frequen-
cy. This strategy is not recommended 
because mutations can occur early 
or late, resulting in substantial mu-
tation frequency fluctuation between 
test episodes. A strain with known 
mutation rates should preferably be 
included to rule out possible techni-
cal errors.
We propose the following expla-
nations for the remarkable results: 1) 
the rifampin concentration for select-
ing mutants might have been too low, 
enabling growth of some colonies of 
drug-susceptible bacteria; 2) rifampin 
mutants arose early or preexisted 
in the cultivation of Beijing strains 
1585 and 1607, producing jackpots; 
or 3) the 2 Beijing isolates might 
contain rifampin-resistant subpopula-
tions (heteroresistance). The capacity 
of the Beijing strain to develop and, 
especially, transmit multidrug-resis-
tant tuberculosis remains to be fur-
ther analyzed.
Jim Werngren
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In Response: We explain the 
differing frequencies of mutation 
to rifampin resistance mentioned 
by Werngren (1). First, the strains 
of Mycobacterium tuberculosis that 
we tested differed from those previ-
ously tested (2). Second, we used 
different rifampin concentrations in 
subculture plates. For Beijing strain 
2002–1585, Bergval et al. (3) found 
a mutation frequency of 4–24 × 10−8 
at a subculture concentration of 8 
mg/L, whereas we found a mutation 
frequency of 3–4 × 10−3 at a subcul-
ture concentration of 1 mg/L and a 
lower mutation frequency at 2 mg/L. 
Thus, the concentration of drugs in 
subculture plates is crucial to mutation 
frequency assays. Absent a subculture 
concentration standard, we applied ri-
fampin at 1 mg/L (4) because bacteria 
growing at this concentration are con-
sidered resistant to rifampin. Our mu-
tation frequency and time-kill kinet-
ics assay results are not contradictory 
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because in the time-kill kinetics as-
says, the subculture rifampin concen-
tration was 4 mg/L.
We performed no classical fluctu-
ation assays. We compared the Beijing 
genotype with the East African/Indian 
genotype to learn how M. tuberculo-
sis strains differed in their capacity to 
withstand antituberculosis drug treat-
ment. For reference strain H37Rv, 
mutation frequency was 1.5 × 10-6, 
higher than that found with higher 
subculture concentrations.
With regard to the 3 other issues, 
our drug-susceptibility testing of mu-
tants showed a stable rifampin-resistant 
phenotype. We agree that these bacteria 
might represent preexisting mutants se-
lected during drug exposure in a certain 
drug concentration window. By using 
different concentrations in subcul-
ture plates in our mutation frequency 
assay, we detected such preexist-
ing mutants. Heteroresistance prob-
ably does not explain our observations 
because in our time-kill kinetics experi-
ments, the whole mycobacterial popu-
lation decreased over time in a drug 
concentration-dependent way, and re-
growth of a drug-resistant subpopula-
tion was not observed.
By not sticking to the fixed test 
conditions as used in the classical 
drug-susceptibility assays, research 
leads to highly interesting findings. 
One can conclude that serendipity 
flourishes with variation.
Jurriaan E.M. de Steenwinkel, 
Dick van Soolingen, and  
Irma A.J.M. Bakker-Woudenberg
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Correction: Vol. 18, No. 8
The name of author Arina Zanuz-
dana was misspelled in the article Vac-
cination of Health Care Workers to Pro-
tect Patients at Increased Risk for Acute 
Respiratory Disease. The article has been 
corrected online (http://wwwnc.cdc.gov/
eid/article/18/8/11-1355_intro.htm).
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